The Division of Cancer Prevention supports major scientific collaborations and research networks at more than100 sites across the United States; investigator-initiated grants; postdoctoral training; and specialized resources for researchers.
Tumor Glycomics Laboratories reveal cancer-related dynamics of carbohydrates for development of validated clinical biomarkers for early detection.
Multidisciplinary translational research centers collaborate to better understand the biology of Barrett's esophagus and esophageal adenocarcinoma to improve risk stratification and develop prevention strategies.
Postdoctoral opportunities provide training in cancer prevention and control to individuals from a multiplicity of health sciences disciplines.
Public and private sector collaborations accelerate the translation of biomarker information and technologies into clinical applications.
A national network of cancer care investigators, providers, academia, and other organizations that will conduct multi-site studies in diverse populations in healthcare systems across the United States.
Six cancer research centers lead multiple collaborative networks to assess potential cancer prevention agents through Phase I and II clinical trials.
This unique partnership facilitates cancer preventive drug development and clinical trials.
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial is a large population-based randomized trial designed and sponsored by the National Cancer Institute (NCI) to determine the effects of screening on cancer-related mortality and secondary endpoints in men and women aged 55 to 74.
Prevents, manages, or treats the symptoms related to cancer, its treatment, quality of life, and at the end of life.
Back to top